>>

>>

抑制剂/激活剂

>>

凋亡与自噬

>>

Acalabrutinib (ACP-196)

Acalabrutinib (ACP-196) ACP-196

Acalabrutinib (ACP-196) 是选择性的第二代BTK抑制剂，抑制B细胞表面原抗体信号通路的激活，IC50为3 nM。它具有很好的靶标特异性，对BTK的选择性比对其他TEC激酶家族成员如ITK、TXK、BMK和TEC的选择性高323-, 94-, 19-, 9-倍。对EGFR没有活性

货号：
TK0352
规格：

2mg

5mg

10mg
价格：
￥0.00

产品参数

CAS No.	1420477-60-6
生物活性	Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL).
分子式	C26H23N7O2
分子量	465.51
储存条件	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
溶解性数据	DMSO : 250 mg/mL (537.05 mM; Need ultrasonic)
体内研究	Acalabrutinib (100 mg twice per day) assessed for thrombus formation at injured arterioles of the mice, exhibits more selective for inhibiting BTK and has virtually no inhibition of platelet activity.
体外研究	Acalabrutinib (ACP-196) inhibits tyrosine phosphorylation of downstream targets of ERK, IKB, and AKT, in the in vitro signaling assay on primary human CLL cells. In the human CLL NSG xenograft model, Acalabrutinib demonstrates on-target effects including decreased phosphorylation of PLCγ2, ERK and significant inhibition of CLL cell proliferation. Acalabrutinib inhibits purified BTK with an IC50 of 3 nM and an EC50 of 8 nM in a human whole-blood CD69 B cell activation assay. Acalabrutinib has improved target specificity over ibrutinib with 323-, 94-, 19-, and 9-fold selectivity over the other TEC kinase family members (ITK, TXK, BMX, and TEC , respectively) and no activity against EGFR.

推荐产品